Ek Joshna, John Bobby, Sharma Ankit, Poorna T Anish, Pangarikar Anunay, Raj Vishnu
Government Dental College, Kottayam, Kerala India.
ESIC Dental College, Kalaburagi, Karnataka India.
Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3530-3534. doi: 10.1007/s12070-023-04016-5. Epub 2023 Jul 4.
The present study aimed to compare the effectiveness of intralesional placentrex versus hyaluronidase + dexamethasone injection in the symptomatic management of stage II OSMF.
This was a non-randomized prospective study conducted over a period of 14 months at a tertiary referral center. Patients with clinical stage II OSMF were randomly grouped into A(n = 18) and B(n = 17). These patients were treated with weekly intralesional injection of placentrex and hyaluronidase + dexamethasone respectively, over a period of six weeks. Variables such as mouth opening, burning sensation and colour of mucosa were evaluated at baseline(T0), second week(T1), fourth week(T3), sixth week(T4) of follow up. A p-value < 0.05 was considered statistically significant.
A total of 15 patients completed the study in each group with regular follow up. The mean improvement in mouth opening was 4.3 ± 0.57 mms in group A(p-value < 0.001) and 7.2 ± 0.76 mms in group B(p-value < 0.001) which were significant at the end of six weeks. Mean change in burning sensation at the end of six weeks in group A was 1.2 ± 0.73(p-value < 0.001), and 3.6 ± 0.63(p-value < 0.001) in group B. Mean change in colour of mucosa at the end of six weeks was 1.4 in group A(p-value > 0.05) and 2 in group B(p-value > 0.05). On comparison between both groups, patients in group B exhibited better mouth opening and reduction of burning sensation than patients in group A(p-value < 0.001).
Both intralesional placentrex and hyaluronidase + dexamethasone injection are effective in alleviating the symptoms of stage II OSMF. However, hyaluronidase + dexamethasone injection showed slightly better improvement in mouth opening and burning sensation after six weeks.
本研究旨在比较病灶内注射胎盘组织液与透明质酸酶+地塞米松注射液对II期口腔黏膜下纤维化症状管理的有效性。
这是一项在三级转诊中心进行的为期14个月的非随机前瞻性研究。临床II期口腔黏膜下纤维化患者被随机分为A组（n = 18）和B组（n = 17）。这些患者分别在六周内每周接受一次病灶内注射胎盘组织液和透明质酸酶+地塞米松治疗。在随访的基线期（T0）、第二周（T1）、第四周（T3）、第六周（T4）评估诸如开口度、烧灼感和黏膜颜色等变量。p值<0.05被认为具有统计学意义。
每组共有15名患者完成了定期随访的研究。六周结束时，A组开口度的平均改善为4.3±0.57毫米（p值<0.001），B组为7.2±0.76毫米（p值<0.001），均具有显著性。六周结束时，A组烧灼感的平均变化为1.2±0.73（p值<0.001），B组为3.6±0.63（p值<0.001）。六周结束时，A组黏膜颜色的平均变化为1.4（p值>0.05），B组为2（p值>0.05）。两组比较，B组患者的开口度和烧灼感减轻情况优于A组患者（p值<0.001）。
病灶内注射胎盘组织液和透明质酸酶+地塞米松注射液均能有效缓解II期口腔黏膜下纤维化的症状。然而，六周后透明质酸酶+地塞米松注射液在开口度和烧灼感改善方面表现略优。
